Dr Sehrish Kanwal
Senior Research Fellow – Specialist
Department of Clinical Pathology
24 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Abstract 7282: A comprehensive multiomics atlas of treatment-naïve breast cancer uncovers co-occurring tumor-immune ecosystems driving immune hot and cold phenotypes
DOI: 10.1158/1538-7445.am2026-72822026
Journal article
Abstract 44: scSubtype2.0: Predictor of breast cancer molecular subtypes at single cell resolution.
DOI: 10.1158/1538-7445.am2026-442025
Journal article
Applying the FAIR Principles to computational workflows
DOI: 10.1038/s41597-025-04451-92025
Journal article
Pathologist-initiated whole genome and transcriptome sequencing demonstrates diagnostic utility in resolving difficult-to-diagnose tumors
DOI: 10.1186/s13073-025-01534-52025
Journal article
Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
DOI: 10.1158/1078-0432.CCR-25-14492025
Other
Supplementary Table S5 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
DOI: 10.1158/1078-0432.306181832025
Other
Supplementary Table S3 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
DOI: 10.1158/1078-0432.30618189
RECENT SCHOLARLY WORKS
2025
Other
Supplementary Figure S5 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
DOI: 10.1158/1078-0432.306182042025
Other
Supplementary Table S1 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
DOI: 10.1158/1078-0432.306182012025
Other
Supplementary Table S2 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
DOI: 10.1158/1078-0432.30618195